New drug BI 3820768 takes on tough cancers in first human trial
NCT ID NCT07306559
First seen Dec 29, 2025
Summary
This study tests a new drug, BI 3820768, in adults with advanced germ cell, endometrial, or ovarian cancers that have not responded to prior treatments. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe and tolerable dose, while checking for tumor shrinkage. Up to 187 participants will receive injections weekly for 6 weeks, then every 3 weeks, for up to 3 years if they benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RELAPSED OR REFRACTORY GERM CELL TUMOURS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cliniques Universitaires Saint-Luc
NOT_YET_RECRUITINGBrussels, 1200, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clínica Universidad de Navarra - Madrid
NOT_YET_RECRUITINGMadrid, 28027, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
INS Paoli-Calmettes
NOT_YET_RECRUITINGMarseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Indiana University
NOT_YET_RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, 94800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Japanese Foundation for Cancer Research
NOT_YET_RECRUITINGTokyo, Koto-ku, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikum der Universität München AÖR
NOT_YET_RECRUITINGMünchen, 81377, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
NOT_YET_RECRUITINGChiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UZ Leuven
SUSPENDEDLeuven, 3000, Belgium
-
Universitätsklinikum Würzburg AÖR
NOT_YET_RECRUITINGWürzburg, 97078, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 3820768
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial, so the drug may not work or may cause side effects. It is the first time BI 3820768 is tested in humans, so results are very uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.